dilluns, 4 d’agost del 2014

What's driving millennials to health tech?




Vector is Children's Hospital Boston's blog about research and innovation in pediatric and adult medicine. We report and comment on medical innovations and advances – from bench to bedside – touching on scientific, business and policy issues. Our ranks include science writers, physicians, lab researchers, market analysts and others inside and outside the hospital.






By Judy Wang



read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1ugKTjy

BSX wins personal injury lawsuit over its Pinnacle pelvic mesh product | Medtech legal news for the week of August 4, 2014




Here's a look at some of the top legal news stories for medical device companies this week: Boston Scientific prevails in 1st pelvic mesh trial; Bard settles more than 500 pelvic mesh complaints; Edwards: Q2 brings double-digit sales bump, a major Medtronic settlement and a rosier outlook on the year; Ex-sales rep's counter-claims stand in poaching spat with Stryker; ResMed kicks Apex sleep masks out of Germany






Boston Scientific prevails in 1st pelvic mesh trial


July 30, 2014 by Brad Perriello




read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1o6qHAd

LensAR raises $8M for laser eye surgery




LensAR secures another $8 million in an equity funding round in support of its laser-based cataract surgery systems.





LensAR raises $8M for laser eye surgery

Opthalmology devices maker LensAR secured $8 million in equity funding, according to an SEC filing dated July 31, 2014.




read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1p4F34t

TAVI study: Sapien tops CoreValve in AR risk, but is CoreValve safer?




A registry study of early TAVI devices finds that patients with Medtronic's CoreValve were more likely to have aortic regurgitation, but patients with Edwards Lifesciences' Sapien fared worse if they had aortic regurgitation.





TAVI study: Sapien tops CoreValve in AR risk, but is CoreValve safer?



read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1p4F2NX

Press Release: Transluminal Technologies receives CE Mark approval for velox CD vascular closure device

Press Release: Transluminal Technologies receives CE Mark approval for velox CD vascular closure device



read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1zNlNfl

Transluminal Tech lands E.U. win for bioabsorbable vascular closure




New York-based Transluminal Technologies touts its 1st CE Mark for the 1st-of-its-kind Velox CD vascular closure system.





Transluminal Tech lands E.U. win for bioabsorbable vascular closure

Transluminal Technologies is ready to take on the European market with CE Mark approval for its flagship Velox CD vascular closure devices.




read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1o5Y6Lu

Curbing risk, not medical innovation, in personalized medicine




FDA's official blog brought to you from FDA's senior leadership and staff stationed at home and abroad - sharing news, background, announcements and other information about the work done at the FDA on behalf of the American public.






By: Jeffrey Shuren, M.D., J.D.


Innovative new tests are routinely submitted to the Food and Drug Administration to assure they are safe and effective. They include genetic tests that help oncologists decide whether a patient is a good candidate for a drug that treats melanoma as well as tests that are capable of sequencing the entire human genome.




read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1qLqnFt